0K9.F - FSD Pharma Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.569
+0.053 (+10.27%)
At close: 7:46PM CEST
Stock chart is not supported by your current browser
Previous Close0.516
Open0.557
Bid0.570 x 0
Ask0.596 x 0
Day's Range0.540 - 0.580
52 Week Range0.078 - 0.589
Volume534,282
Avg. Volume932,065
Market Cap771.473M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.009
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • FSD Pharma Announces Upgraded Listing to OTCQB Venture Market
    CNW Group2 days ago

    FSD Pharma Announces Upgraded Listing to OTCQB Venture Market

    FSD Pharma Announces Upgraded Listing to OTCQB Venture Market

  • FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms
    CNW Group3 days ago

    FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms

    TORONTO , Sept.18, 2018 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement") with Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market, effective September 17, 2018 . Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").

  • FSD Pharma joins Snipp's Cannabis Marketing Resource Center
    CNW Group4 days ago

    FSD Pharma joins Snipp's Cannabis Marketing Resource Center

    FSD Pharma joins Snipp's Cannabis Marketing Resource Center

  • FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica
    CNW Group8 days ago

    FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica

    FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica

  • FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History
    CNW Group9 days ago

    FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History

    TORONTO , Sept. 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F), is pleased to report that on September 11, 2018 the Company traded an aggregate total of exactly 213,761,823 shares. FSD traded 143,260,988 Class B subordinate voting shares on the Canadian Securities Exchange ("CSE"), 1,888,500 on AQC-Lit, 15,369,000 on AQC-Neo, 241,740 on CXC, 5,309,399 on CX2, 6,473,592 on CXD, 22,500 on Lynx, 24,750,500 on Omega and 16,445,604 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 15.7% above the recorded all-time high of 184,718,114 also achieved by FSD on September 10, 2018 , as confirmed by the CSE.

  • FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing
    CNW Group10 days ago

    FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing

    TORONTO , Sept. 11, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the "Options") on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director. The Board has also approved an additional grant of 40,000,000 Options to Dr. Bokhari exercisable at a price of $0.74 for a period of five years.

  • FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation
    CNW Group14 days ago

    FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation

    FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation

  • FSD Pharma breaks all-time daily volume record and makes history again
    CNW Group16 days ago

    FSD Pharma breaks all-time daily volume record and makes history again

    FSD Pharma breaks all-time daily volume record and makes history again

  • FSD Pharma Reports Q2 Results
    CNW Group21 days ago

    FSD Pharma Reports Q2 Results

    TORONTO , Aug. 30, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30 th, 2018.   These filings are available for review on the Company's SEDAR profile at www.sedar.com. FSD Pharma continues to make Strategic early stage investments in the Cannabis industry with like minded companies that 1) provide excellent investment potential and 2) will assist FSD strategically in its business.  An example of this is evidenced by this quarters mark to market asset revaluation of FSD's holding in Cannara Biotech resulting in a $7,500,000 gain.

  • FSD Pharma reports positive pre-clinical results for proprietary CBD combination product
    CNW Group29 days ago

    FSD Pharma reports positive pre-clinical results for proprietary CBD combination product

    TORONTO , Aug. 23, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) reports today that its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann"), has achieved positive results in a pre-clinical efficacy study of its proprietary "Steady Stomach" CBD combination product for Inflammatory Bowel Disease (IBD).

  • FSD Pharma Completes Harvest and Microbial Testing of First Lot
    CNW Grouplast month

    FSD Pharma Completes Harvest and Microbial Testing of First Lot

    FSD Pharma Completes Harvest and Microbial Testing of First Lot

  • FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel
    CNW Grouplast month

    FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel

    This comprehensive clinical research program will be executed through SciCann's strategic alliance and collaboration agreement with Mor Research Applications Ltd. ("Mor") - the technology transfer office and commercial arm of Clalit Healthcare Services, Israel's largest medical insurer and healthcare provider, which operates a network of 14 full scale hospitals throughout Israel , employs over 9,000 physicians and serves the healthcare needs of over 50% of Israel's population.